Global Blood Therapeutics (GBT) Tops Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to Global Blood Therapeutics (GBT) Tops Q2 EPS by 7c

GBT Reports Second Quarter 2021 Financial Results

August 3, 2021 4:05 PM EDT

Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year

Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in Europe   

Advanced pipeline with initiation of two inclacumab pivotal Phase 3 trials and GBT021601 (GBT601) Phase 1 trial   Conference call today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported financial results for the second quarter ended June 30, 2021 and... More